Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990-2017.

Age Distribution Aortic Valve / diagnostic imaging Aortic Valve Insufficiency / diagnostic imaging Aortic Valve Stenosis / diagnostic imaging Calcinosis / diagnostic imaging Cost of Illness Female Global Health Health Status Disparities Healthcare Disparities Humans Male Mitral Valve Insufficiency / diagnostic imaging Mitral Valve Prolapse / diagnostic imaging Prevalence Quality of Life Risk Assessment Risk Factors Time Factors
aortic valve global burden of disease heart valve diseases mitral valve

Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
26 05 2020
Historique:
pubmed: 1 4 2020
medline: 8 6 2021
entrez: 1 4 2020
Statut: ppublish

Résumé

Nonrheumatic valvular diseases are common; however, no studies have estimated their global or national burden. As part of the Global Burden of Disease Study 2017, mortality, prevalence, and disability-adjusted life-years (DALYs) for calcific aortic valve disease (CAVD), degenerative mitral valve disease, and other nonrheumatic valvular diseases were estimated for 195 countries and territories from 1990 to 2017. Vital registration data, epidemiologic survey data, and administrative hospital data were used to estimate disease burden using the Global Burden of Disease Study modeling framework, which ensures comparability across locations. Geospatial statistical methods were used to estimate disease for all countries, because data on nonrheumatic valvular diseases are extremely limited for some regions of the world, such as Sub-Saharan Africa and South Asia. Results accounted for estimated level of disease severity as well as the estimated availability of valve repair or replacement procedures. DALYs and other measures of health-related burden were generated for both sexes and each 5-year age group, location, and year from 1990 to 2017. Globally, CAVD and degenerative mitral valve disease caused 102 700 (95% uncertainty interval [UI], 82 700-107 900) and 35 700 (95% UI, 30 500-42 500) deaths, and 12.6 million (95% UI, 11.4 million-13.8 million) and 18.1 million (95% UI, 17.6 million-18.6 million) prevalent cases existed in 2017, respectively. A total of 2.5 million (95% UI, 2.3 million-2.8 million) DALYs were estimated as caused by nonrheumatic valvular diseases globally, representing 0.10% (95% UI, 0.09%-0.11%) of total lost health from all diseases in 2017. The number of DALYs increased for CAVD and degenerative mitral valve disease between 1990 and 2017 by 101% (95% UI, 79%-117%) and 35% (95% UI, 23%-47%), respectively. There is significant geographic variation in the prevalence, mortality rate, and overall burden of these diseases, with highest age-standardized DALY rates of CAVD estimated for high-income countries. These global and national estimates demonstrate that CAVD and degenerative mitral valve disease are important causes of disease burden among older adults. Efforts to clarify modifiable risk factors and improve access to valve interventions are necessary if progress is to be made toward reducing, and eventually eliminating, the burden of these highly treatable diseases.

Sections du résumé

BACKGROUND
Nonrheumatic valvular diseases are common; however, no studies have estimated their global or national burden. As part of the Global Burden of Disease Study 2017, mortality, prevalence, and disability-adjusted life-years (DALYs) for calcific aortic valve disease (CAVD), degenerative mitral valve disease, and other nonrheumatic valvular diseases were estimated for 195 countries and territories from 1990 to 2017.
METHODS
Vital registration data, epidemiologic survey data, and administrative hospital data were used to estimate disease burden using the Global Burden of Disease Study modeling framework, which ensures comparability across locations. Geospatial statistical methods were used to estimate disease for all countries, because data on nonrheumatic valvular diseases are extremely limited for some regions of the world, such as Sub-Saharan Africa and South Asia. Results accounted for estimated level of disease severity as well as the estimated availability of valve repair or replacement procedures. DALYs and other measures of health-related burden were generated for both sexes and each 5-year age group, location, and year from 1990 to 2017.
RESULTS
Globally, CAVD and degenerative mitral valve disease caused 102 700 (95% uncertainty interval [UI], 82 700-107 900) and 35 700 (95% UI, 30 500-42 500) deaths, and 12.6 million (95% UI, 11.4 million-13.8 million) and 18.1 million (95% UI, 17.6 million-18.6 million) prevalent cases existed in 2017, respectively. A total of 2.5 million (95% UI, 2.3 million-2.8 million) DALYs were estimated as caused by nonrheumatic valvular diseases globally, representing 0.10% (95% UI, 0.09%-0.11%) of total lost health from all diseases in 2017. The number of DALYs increased for CAVD and degenerative mitral valve disease between 1990 and 2017 by 101% (95% UI, 79%-117%) and 35% (95% UI, 23%-47%), respectively. There is significant geographic variation in the prevalence, mortality rate, and overall burden of these diseases, with highest age-standardized DALY rates of CAVD estimated for high-income countries.
CONCLUSIONS
These global and national estimates demonstrate that CAVD and degenerative mitral valve disease are important causes of disease burden among older adults. Efforts to clarify modifiable risk factors and improve access to valve interventions are necessary if progress is to be made toward reducing, and eventually eliminating, the burden of these highly treatable diseases.

Identifiants

DOI: 10.1161/CIRCULATIONAHA.119.043391 PMID: 32223336
pubmed: 32223336
doi: 10.1161/CIRCULATIONAHA.119.043391
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't Webcast

Langues

eng

Sous-ensembles de citation

IM

Pagination

1670-1680

Commentaires et corrections

Type : ErratumIn

Auteurs

Simon Yadgir (S)

Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.

Catherine Owens Johnson (CO)

Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.

Victor Aboyans (V)

Department of Cardiology, Dupuytren University Hospital, Limoges, France (V. Aboyans).
Institute of Epidemiology, University of Limoges, France (V. Aboyans).

Oladimeji M Adebayo (OM)

College of Medicine, University College Hospital, College of Medicine, University College Hospital, Ibadan, Oyo, Nigeria (O.M.A.).

Rufus Adesoji Adedoyin (RA)

Department of Medical Rehabilitation, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria (R.A.A.).

Mohsen Afarideh (M)

Endocrinology and Metabolism Research Center (M.A., A.E.), Tehran University of Medical Sciences, Iran.

Fares Alahdab (F)

Evidence Based Practice Center, Mayo Clinic Foundation for Medical Education and Research, Rochester, MN (F.A.).

Alaa Alashi (A)

Department of Cardiovascular Medicine (A.A., M.M.G.), Cleveland Clinic, OH.

Vahid Alipour (V)

Health Management and Economics Research Center (V. Alipour, J.A., S.A., A. Rezapour), Iran University of Medical Sciences, Tehran.
Health Economics Department (V. Alipour), Iran University of Medical Sciences, Tehran.

Jalal Arabloo (J)

Health Management and Economics Research Center (V. Alipour, J.A., S.A., A. Rezapour), Iran University of Medical Sciences, Tehran.

Samad Azari (S)

Health Management and Economics Research Center (V. Alipour, J.A., S.A., A. Rezapour), Iran University of Medical Sciences, Tehran.

Celine M Barthelemy (CM)

Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.

Catherine P Benziger (CP)

Heart and Vascular Center, Essentia Health, Duluth, MN (C.P.B.).

Adam E Berman (AE)

Department of Medicine, Medical College of Georgia at Augusta University (A.E.B.).

Ali Bijani (A)

Social Determinants of Health Research Center, Babol University of Medical Sciences, Mazandaran, Iran (A.B.).

Juan J Carrero (JJ)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (J.J.C.).

Félix Carvalho (F)

Applied Molecular Biosciences Unit (F.C.), University of Porto, Portugal.
Institute of Public Health (F.C.), University of Porto, Portugal.

Ahmad Daryani (A)

Andre R Durães (AR)

Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran (A.D.).
School of Medicine, Federal University of Bahia, Salvador, Brazil (A.R.D.).

Alireza Esteghamati (A)

Endocrinology and Metabolism Research Center (M.A., A.E.), Tehran University of Medical Sciences, Iran.

Talha A Farid (TA)

Division of Cardiovascular Medicine, University of Louisville, KY (T.A.F., A.R.K.).

Farshad Farzadfar (F)

Non-communicable Diseases Research Center (F.F.), Tehran University of Medical Sciences, Iran.

Eduarda Fernandes (E)

REQUIMTE/LAQV (E.F.), University of Porto, Portugal.

Irina Filip (I)

Psychiatry Department, Kaiser Permanente, Fontana, CA (I.F.).
Department of Health Sciences, A.T. Still University, Mesa, AZ (I.F.).

Mohamed M Gad (MM)

Department of Cardiovascular Medicine (A.A., M.M.G.), Cleveland Clinic, OH.
Gillings School of Global Public Health, University of North Carolina Chapel Hill (M.M.G.).

Samer Hamidi (S)

School of Health and Environmental Studies, Hamdan Bin Mohammed Smart University, Dubai, United Arab Emirates (S.H.).

Simon I Hay (SI)

Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.
School of Medicine (S.I.H.), University of Washington, Seattle.
Department of Cardiology, Dupuytren University Hospital, Limoges, France (V. Aboyans).

Olayinka Stephen Ilesanmi (OS)

Department of Community Medicine, University of Ibadan, Nigeria (O.S.I.).

Seyed Sina Naghibi Irvani (SS)

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran (S.S.N.I.).

Mikk Jürisson (M)

Institute of Family Medicine and Public Health, University of Tartu, Tartumaa, Estonia (M.J.).

Amir Kasaeian (A)

Hematology-Oncology and Stem Cell Transplantation Research Center (A. Kasaeian), Tehran University of Medical Sciences, Iran.
Hematologic Malignancies Research Center (A. Kasaeian), Tehran University of Medical Sciences, Iran.

Andre Pascal Kengne (AP)

Non-communicable Diseases Research Unit, Medical Research Council South Africa, Cape Town (A.P.K.).
Department of Medicine, University of Cape Town, South Africa (A.P.K., G.A.M., K.S.).

Abdur Rahman Khan (AR)

Division of Cardiovascular Medicine, University of Louisville, KY (T.A.F., A.R.K.).

Adnan Kisa (A)

Department of Health Management and Health Economics, Kristiania University College, Oslo, Norway (A. Kisa).
Department of Health Services Policy and Management, University of South Carolina, Columbia (A. Kisa).

Sezer Kisa (S)

Department of Nursing and Health Promotion, Oslo Metropolitan University, Norway (S.K.).

Dhaval Kolte (D)

Department of Medicine, Brown University, Providence, RI (D.K.).

Navid Manafi (N)

Ophthalmology Department (N.M.), Iran University of Medical Sciences, Tehran.
Ophthalmology Department, University of Manitoba, Winnipeg, Canada (N.M.).

Amir Manafi (A)

Department of Surgery, University of Virginia, Charlottesville (A.M.).

George A Mensah (GA)

Department of Medicine, University of Cape Town, South Africa (A.P.K., G.A.M., K.S.).
Center for Translation Research and Implementation Science, National Institutes of Health, Bethesda, MD (G.A.M.).

Erkin M Mirrakhimov (EM)

Faculty of General Medicine, Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan (E.M.M.).
Department of Atherosclerosis and Coronary Heart Disease, National Center of Cardiology and Internal Disease, Bishkek, Kyrgyzstan (E.M.M.).

Yousef Mohammad (Y)

Internal Medicine Department, King Saud University, Riyadh, Saudi Arabia (Y.M.).

Ali H Mokdad (AH)

Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.
Department of Health Metrics Sciences (A.H.M., G.A.R.), University of Washington, Seattle.

Ruxandra Irina Negoi (RI)

Anatomy and Embryology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania (R.I.N.).
Department of Cardiology, Cardio-Aid, Bucharest, Romania (R.I.N.).

Huong Lan Thi Nguyen (HL)

Institute for Global Health Innovations, Duy Tan University, Hanoi, Vietnam (H.L.T.N.).

Trang Huyen Nguyen (TH)

Center of Excellence in Behavioral Health, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam (T.H.N.).

Molly R Nixon (MR)

Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.

Catherine M Otto (CM)

Division of Cardiology (C.M.O., G.A.R.), University of Washington, Seattle.

Shanti Patel (S)

Department of Medicine, Maimonides Medical Center, Brooklyn, NY (S.P.).

Thomas Pilgrim (T)

Department of Cardiology, University of Bern, Switzerland (T.P.).

Amir Radfar (A)

College of Graduate Health Sciences, A.T. Still University, Mesa, AZ (A. Radfar).
Medichem, Barcelona, Spain (A. Radfar).

David Laith Rawaf (DL)

WHO Collaborating Centre for Public Health Education and Training (D.L.R.), Imperial College London, United Kingdom.
University College London Hospitals, United Kingdom (D.L.R.).

Salman Rawaf (S)

Department of Primary Care and Public Health (S.R.), Imperial College London, United Kingdom.
Public Health England, London, United Kingdom (S.R.).

Wasiq Faraz Rawasia (WF)

Cardiovascular Medicine, West Virginia University, Morgantown (W.F.R.).

Aziz Rezapour (A)

Health Management and Economics Research Center (V. Alipour, J.A., S.A., A. Rezapour), Iran University of Medical Sciences, Tehran.

Leonardo Roever (L)

Department of Clinical Research, Federal University of Uberl ândia, Brazil (L.R.).

Anas M Saad (AM)

Faculty of Medicine, Ain Shams University, Cairo, Egypt (A.M.S.).

Seyedmohammad Saadatagah (S)

Department of Cardiology (S. Saadatagah), Tehran University of Medical Sciences, Iran.

Subramanian Senthilkumaran (S)

Emergency Department, Manian Medical Centre, ERODE, Tamil Nadu, India (S. Senthilkumaran).

Karen Sliwa (K)

Department of Medicine, University of Cape Town, South Africa (A.P.K., G.A.M., K.S.).

Berhe Etsay Tesfay (BE)

Department of Public Health, Adigrat University, Tigray, Ethiopia (B.E.T.).

Bach Xuan Tran (BX)

Department of Health Economics, Hanoi Medical University, Vietnam (B.X.T.).

Irfan Ullah (I)

Gomal Center of Biochemistry and Biotechnology, Gomal University, Faisalabad, Pakistan (I.U.).
TB Culture Laboratory, Mufti Mehmood Memorial Teaching Hospital, Dera Ismail Khan, Khyber Pakhtunkhwa, Pakistan (I.U.).

Muthiah Vaduganathan (M)

Heart and Vascular Center, Harvard University, Boston, MA (M.V.).

Tommi Juhani Vasankari (TJ)

UKK Institute, Tampere, Finland (T.J.V.).

Charles D A Wolfe (CDA)

School of Population Health & Environmental Sciences, King's College London, United Kingdom (C.D.A.W.).
Biomedical Research Council, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom (C.D.A.W.).

Naohiro Yonemoto (N)

Department of Psychopharmacology, National Center of Neurology and Psychiatry, Tokyo, Japan (N.Y.).

Gregory A Roth (GA)

Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.
Department of Health Metrics Sciences (A.H.M., G.A.R.), University of Washington, Seattle.
Division of Cardiology (C.M.O., G.A.R.), University of Washington, Seattle.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › Répartition par âge › Global, Regional, and National Burden of...
questionsmedicales.fr › Système cardiovasculaire › Coeur › Valves cardiaques › Valve aortique › Global, Regional, and National Burden of...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Valvulopathies › Maladie de la valve aortique › Insuffisance aortique › Global, Regional, and National Burden of...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Obstacle à l'éjection ventriculaire › Sténose aortique › Global, Regional, and National Burden of...
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Troubles du métabolisme du calcium › Calcinose › Global, Regional, and National Burden of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes de santé › Indicateurs d'état de santé › Coûts indirects de la maladie › Global, Regional, and National Burden of...
questionsmedicales.fr › Caractéristiques de la population › Santé › Santé mondiale › Global, Regional, and National Burden of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Disparités de l'état de santé › Global, Regional, and National Burden of...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Prestations des soins de santé › Disparités d'accès aux soins › Global, Regional, and National Burden of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Global, Regional, and National Burden of...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Valvulopathies › Insuffisance mitrale › Global, Regional, and National Burden of...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Valvulopathies › Prolapsus des valves cardiaques › Prolapsus de la valve mitrale › Global, Regional, and National Burden of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Prévalence › Global, Regional, and National Burden of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › Global, Regional, and National Burden of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Appréciation des risques › Global, Regional, and National Burden of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Global, Regional, and National Burden of...
questionsmedicales.fr › Phénomènes physiques › Temps › Facteurs temps › Global, Regional, and National Burden of...